Intas' highly advanced EU-GMP Certified Biopharma Unit was launched in 2000 with a focus on developing, manufacturing and marketing Bio similar of world-class quality. It is fuelled by a mission to provide affordable “biosimilars for billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. With filgrastim, Intas became the first-ever Indian company to launch a biosimilar in the highly regulated EU market [approved and marketed under the name Accofil™]. In 2018, it also became the first integrated player to launch a pegfilgrastim bio similar across Europe [approved and marketed under the name Pelgraz™].

Today, the unit caters to highly regulated markets of the EU, UK and US, which demand the highest standards of drug quality.